Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.

Autor: Moysidou GS; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece.; 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University Faculty of Medicine, Athens, Greece., Garantziotis P; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece.; Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany., Sentis G; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece., Nikoleri D; Laboratory of Auoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece., Malissovas N; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece., Nikoloudaki M; Rheumatology, Clinical Immunology and Allergy Department, University of Crete School of Medicine, Heraklion, Greece., Stergioti EM; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece., Polia S; Rheumatology, Clinical Immunology and Allergy Department, University of Crete School of Medicine, Heraklion, Greece., Paschalidis N; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece., Filia A; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece., Grigoriou M; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece.; 1st Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace - Alexandropoulis Campus, Alexandroupolis, Greece., Nikolopoulos D; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece.; Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden., Kapsala N; 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University Faculty of Medicine, Athens, Greece., Katechis S; 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University School of Medicine, Athens, Greece., Fanouriakis A; 4th Department of Medicine, National and Kapodistrian University Faculty of Medicine, Athens, Greece., Bertsias G; Rheumatology, Clinical Immunology and Allergy Department, University of Crete School of Medicine, Heraklion, Greece.; Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece., Boumpas DT; Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece boumpasd@uoc.gr.; 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University Faculty of Medicine, Athens, Greece.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Nov 13. Date of Electronic Publication: 2024 Nov 13.

Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis.

Autor: Anyfanti P; Second Medical Department, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Angeloudi E; Second Medical Department, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Dara A; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Pagkopoulou E; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Moysidou GS; Rheumatology-Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece., Deuteraiou K; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Boutel M; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Bekiari E; Second Medical Department, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Doumas M; 2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece., Kitas GD; Department of Rheumatology, Russells Hall Hospital, Dudley Group NHS Foundation Trust, Dudley DY1 2HQ, UK.; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham B15 2TT, UK., Dimitroulas T; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Publikováno v: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2024 Apr 17; Vol. 14 (8). Date of Electronic Publication: 2024 Apr 17.

JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus.

Autor: Moysidou GS; National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece; Inflammation and Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece., Dara A; Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Publikováno v: Mediterranean journal of rheumatology [Mediterr J Rheumatol] 2024 Mar 30; Vol. 35 (Suppl 1), pp. 37-44. Date of Electronic Publication: 2024 Mar 30 (Print Publication: 2024).

Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.

Autor: Moysidou GS; Department of Rheumatology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Paris, France., Marotte H; Department of Rheumatology, Université St Etienne, and CRI-IMIDIATE Clinical Research Infrastructure Network, Paris, France., Kossi S; Department of Rheumatology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Paris, France., Tubach F; CRI-IMIDIATE Clinical Research Infrastructure Network, Paris; INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, PEPITES Team, Paris, and Department of Biostatistics, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Paris, France., Hajage D; INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, PEPITES Team, Paris, and Department of Biostatistics, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Paris, France., Fautrel B; Department of Rheumatology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Paris; CRI-IMIDIATE Clinical Research Infrastructure Network, Paris, and INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, PEPITES Team, Paris, France. bruno.fautrel@aphp.fr.

Publikováno v: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2023 Sep; Vol. 41 (9), pp. 1831-1837. Date of Electronic Publication: 2023 Jul 24.

Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study.

Autor: Moysidou GS; Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.; Faculty of Medicine, National and Kapodistrian University of Athens, Inflammation & Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece., Garantziotis P; Faculty of Medicine, National and Kapodistrian University of Athens, Inflammation & Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece., Nikolopoulos D; Faculty of Medicine, National and Kapodistrian University of Athens, Inflammation & Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece., Katsimbri P; Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece., Fanouriakis A; Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.; 1st Department of Propaedeutic Internal Medicine, 'Laiko' General Hospital, Athens, Greece.; Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece., Boumpas DT; Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.; Faculty of Medicine, National and Kapodistrian University of Athens, Inflammation & Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.; Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Publikováno v: Lupus [Lupus] 2023 Feb; Vol. 32 (2), pp. 225-230. Date of Electronic Publication: 2022 Dec 09.